Literature DB >> 31371229

More questions regarding HIPEC in colorectal carcinomatosis.

Benny Johnson1, Cathy Eng2.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31371229     DOI: 10.1016/S2468-1253(19)30254-7

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


× No keyword cloud information.
  3 in total

Review 1.  Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review.

Authors:  Peilin Dai; Zaisheng Ye; Zhai Cai; Zeyu Luo; Enming Qiu; Yu Lin; Jian Cai; Hui Wang; Zhou Li; Shuai Han
Journal:  BMC Gastroenterol       Date:  2022-02-14       Impact factor: 3.067

2.  Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study - protocol for a randomised, multicentre, phase 3 trial.

Authors:  Fabio Pacelli; Chiara Gerardi; Eliana Rulli; Carlo Abatini; Stefano Rotolo; Silvio Garattini; Gianluigi Melotti; Valter Torri; Fabio Galli; Erica Rulli; Andrea Di Giorgio
Journal:  BMJ Open       Date:  2022-08-01       Impact factor: 3.006

3.  Development and Validation of a Prognostic Nomogram for Colorectal Cancer Patients With Synchronous Peritoneal Metastasis.

Authors:  Zifeng Yang; Yong Li; Xiusen Qin; Zejian Lv; Huaiming Wang; Deqing Wu; Zixu Yuan; Hui Wang
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.